- Home
- DVAX vs PZZA Comparison
DVAX vs PZZA Comparison
Compare DVAX & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- PZZA
- Stock Information
- Founded
- DVAX 1996
- PZZA 1984
- Country
- DVAX United States
- PZZA United States
- Employees
- DVAX N/A
- PZZA N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- PZZA Restaurants
- Sector
- DVAX Health Care
- PZZA Consumer Discretionary
- Exchange
- DVAX Nasdaq
- PZZA Nasdaq
- Market Cap
- DVAX 1.7B
- PZZA 1.6B
- IPO Year
- DVAX 2004
- PZZA 1993
- Fundamental
- Price
- DVAX $12.90
- PZZA $41.96
- Analyst Decision
- DVAX Buy
- PZZA Buy
- Analyst Count
- DVAX 2
- PZZA 13
- Target Price
- DVAX $22.00
- PZZA $61.90
- AVG Volume (30 Days)
- DVAX 1.3M
- PZZA 996.4K
- Earning Date
- DVAX 11-07-2024
- PZZA 11-07-2024
- Dividend Yield
- DVAX N/A
- PZZA 4.37%
- EPS Growth
- DVAX N/A
- PZZA 22.68
- EPS
- DVAX 0.15
- PZZA 2.89
- Revenue
- DVAX $260,810,000.00
- PZZA $2,099,938,999.00
- Revenue This Year
- DVAX $21.64
- PZZA N/A
- Revenue Next Year
- DVAX $19.81
- PZZA $1.87
- P/E Ratio
- DVAX $85.33
- PZZA $14.59
- Revenue Growth
- DVAX N/A
- PZZA 0.45
- 52 Week Low
- DVAX $9.74
- PZZA $39.90
- 52 Week High
- DVAX $15.01
- PZZA $78.67
- Technical
- Relative Strength Index (RSI)
- DVAX 57.32
- PZZA 29.14
- Support Level
- DVAX $12.66
- PZZA $47.54
- Resistance Level
- DVAX $13.17
- PZZA $50.85
- Average True Range (ATR)
- DVAX 0.29
- PZZA 1.82
- MACD
- DVAX -0.04
- PZZA -0.66
- Stochastic Oscillator
- DVAX 48.08
- PZZA 4.13
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 5,900 restaurants across nearly 50 countries at the end of 2023. The firm operates a predominantly franchised system, owning 11% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain both in the US and globally, with a sizable presence in the UK, China, South Korea, and Chile.